**citizens jmp reiterates market outperform rating on kura oncology stock**

Kura Oncology received reaffirmed Market Outperform rating from Citizens JMP with a $28 price target following positive data from the KOMET-001 trial of ziftomenib in r/r NPM1-m AML presented at ASCO, showing a 23% CR/CRh rate. The FDA accepted the NDA for ziftomenib with priority review and a PDUFA date of November 30, 2025, while analysts from Leerink Partners, Cantor Fitzgerald, and H.C. Wainwright have all reiterated positive ratings for Kura Oncology. Kura Oncology plans to initiate fully funded frontline trials in the second half of 2025, supported by a pro forma cash position of $703.2 million.

Analysis

Kura Oncology (NASDAQ:KURA) has recently experienced significant positive developments, primarily driven by promising results from its KOMET-001 trial for ziftomenib in treating relapsed or refractory NPM1-mutated acute myeloid leukemia (r/r NPM1-m AML). The trial reported a 23% complete response/complete response with partial hematologic recovery (CR/CRh) rate, a median duration of response (mDOR) of 3.7 months, and a 63% minimal residual disease (MRD) negative rate, meeting expectations. Reinforcing this clinical progress, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for ziftomenib, granting it priority review status with a Prescription Drug User Fee Act (PDUFA) date set for November 30, 2025. Analyst sentiment is strongly supportive, with Citizens JMP reaffirming a Market Outperform rating and a $28 price target, significantly above the stock's current price of $6.42; this is echoed by positive ratings from Leerink Partners, Cantor Fitzgerald, and H.C. Wainwright, and a consensus recommendation of 1.47 (Strong Buy) with targets ranging $8-$40. The stock has responded positively, gaining 15.68% in the past week. Kura Oncology's financial health appears robust, with a pro forma cash position of $703.2 million and a current ratio of 8.07, sufficiently funding operations through the PDUFA date and enabling the initiation of fully funded frontline trials in the second half of 2025.

Key Decisions for Investors

• Investors should consider the significant upside potential implied by the strong analyst consensus and price targets, especially relative to Kura Oncology's current share price, following positive ziftomenib trial data and FDA priority review.
• The PDUFA date of November 30, 2025, represents a critical binary event that will significantly impact the company's valuation, warranting close attention.
• Monitoring upcoming data from the KOMET-007 study at the European Hematology Association Congress is advisable for further insight into the clinical pipeline's strength and ziftomenib's competitive positioning, particularly its noted safety advantages.